DTX Pharma Inc.
Doing business as DTX Pharma
- UEI
- QH4NQ868H5V7
- CAGE
- 7WYE4
- Primary NAICS
- Not on record
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Website
- novartis.com
- Founded
- 1996
- Employees
- 100K+
- Estimated annual revenue
- $10B+
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Development of an RNA therapeutic for the treatment of charcot marie tooth 1A | Defense Health Agency | $0 | |
| Development of PMP22 sirna conjugates for treatment of charcot-marie-tooth disease type 1A | National Institute of Neurological Disorders and Stroke | $387,925 | |
| Reversal of TAU pathology with MSUT2 sirna conjugates | National Institute on Aging | $461,892 | |
| Generation of potent, safe and deliverable human TAU targeting sirna for treatment of tauopathies | National Institute on Aging | $159,604 | |
| Systemic characterization of novel lipidated sirna conjugates | National Center for Advancing Translational Sciences | $321,555 |
About DTX Pharma Inc.
DTX Pharma Inc., doing business as DTX Pharma, is a for-profit biotechnology company that provides healthcare solutions to improve and extend people's lives through science-based innovation. DTX Pharma specializes in developing RNA therapeutics for the treatment of neurological and genetic disorders.
Through past federal grants, DTX Pharma has conducted research and development of RNA therapeutics targeting neurological conditions such as Charcot Marie Tooth disease and tauopathies like Alzheimer's disease. This work has been funded primarily through Project Grants from the National Institutes of Health, with additional support from the Defense Health Agency's Military Medical Research and Development program. Specific projects have focused on developing siRNA conjugates to treat Charcot Marie Tooth Type 1A, reversing tau pathology in Alzheimer's models using siRNA conjugates, generating siRNAs targeting tau for treatment of tauopathies, and systemic characterization of novel lipidated siRNA conjugates. In total, DTX Pharma has been awarded over $5.5 million in federal grants to advance RNA therapeutics through the Applied Research stage of the research pipeline. The company has partnered with government agencies including the National Institute of Neurological Disorders and Stroke, National Institute on Aging, and National Center for Advancing Translational Sciences.
Quick answers
What is DTX Pharma Inc.'s UEI?
DTX Pharma Inc.'s Unique Entity ID (UEI) in SAM.gov is QH4NQ868H5V7.
What is DTX Pharma Inc.'s CAGE code?
DTX Pharma Inc.'s CAGE code is 7WYE4.
Is DTX Pharma Inc. registered in SAM.gov?
DTX Pharma Inc.'s SAM.gov registration expired on December 13, 2023.
What is DTX Pharma Inc.'s most recent federal award?
DTX Pharma Inc.'s most recent federal grant award is Development of an RNA therapeutic for the treatment of charcot marie tooth 1A (HT94252310470), from Defense Health Agency, on June 15, 2023.
On GovTribe
See DTX Pharma Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors